Cargando…

Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival

BACKGROUND: In Asia, large-scale studies on anti-HER2 treatment in HER2-positive breast cancer patients with brain metastases are limited. We studied the treatment patterns of these patients in Asia to evaluate the impact of anti-HER2 treatment on the time to occurrence of brain metastases (TTBM) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yap, Y S, Cornelio, G H, Devi, B C R, Khorprasert, C, Kim, S B, Kim, T Y, Lee, S C, Park, Y H, Sohn, J H, Sutandyo, N, Wong, D W Y, Kobayashi, M, Landis, S H, Yeoh, E M, Moon, H, Ro, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461152/
https://www.ncbi.nlm.nih.gov/pubmed/22918394
http://dx.doi.org/10.1038/bjc.2012.346
_version_ 1782245044163444736
author Yap, Y S
Cornelio, G H
Devi, B C R
Khorprasert, C
Kim, S B
Kim, T Y
Lee, S C
Park, Y H
Sohn, J H
Sutandyo, N
Wong, D W Y
Kobayashi, M
Landis, S H
Yeoh, E M
Moon, H
Ro, J
author_facet Yap, Y S
Cornelio, G H
Devi, B C R
Khorprasert, C
Kim, S B
Kim, T Y
Lee, S C
Park, Y H
Sohn, J H
Sutandyo, N
Wong, D W Y
Kobayashi, M
Landis, S H
Yeoh, E M
Moon, H
Ro, J
author_sort Yap, Y S
collection PubMed
description BACKGROUND: In Asia, large-scale studies on anti-HER2 treatment in HER2-positive breast cancer patients with brain metastases are limited. We studied the treatment patterns of these patients in Asia to evaluate the impact of anti-HER2 treatment on the time to occurrence of brain metastases (TTBM) and survival after brain metastasis (BM). METHODS: A retrospective study of HER2-positive breast cancer patients diagnosed with BM between January 2006 and December 2008 in six Asian countries was conducted. Demographics, tumour characteristics, treatment details, and events dates were collected from medical records. RESULTS: Data from 280 patients were analysed. Before BM, 63% received anti-HER2 treatment. These patients had significantly longer TTBM than those without anti-HER2 treatment (median 33 vs 19 months; P<0.002). After BM, 93% received radiotherapy, 57% received chemotherapy, and 41% received anti-HER2 treatment (trastuzumab and/or lapatinib). Use of both anti-HER2 agents, primarily sequentially, after BM demonstrated the longest survival after BM and was associated with a significant survival benefit over no anti-HER2 treatment (median 26 vs 6 months; hazard ratio 0.37; 95% CI 0.19–0.72). CONCLUSION: Anti-HER2 treatment before BM was associated with longer TTBM. Anti-HER2 treatment after BM was associated with a survival benefit, especially when both trastuzumab and lapatinib were utilised.
format Online
Article
Text
id pubmed-3461152
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-34611522012-10-04 Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival Yap, Y S Cornelio, G H Devi, B C R Khorprasert, C Kim, S B Kim, T Y Lee, S C Park, Y H Sohn, J H Sutandyo, N Wong, D W Y Kobayashi, M Landis, S H Yeoh, E M Moon, H Ro, J Br J Cancer Clinical Study BACKGROUND: In Asia, large-scale studies on anti-HER2 treatment in HER2-positive breast cancer patients with brain metastases are limited. We studied the treatment patterns of these patients in Asia to evaluate the impact of anti-HER2 treatment on the time to occurrence of brain metastases (TTBM) and survival after brain metastasis (BM). METHODS: A retrospective study of HER2-positive breast cancer patients diagnosed with BM between January 2006 and December 2008 in six Asian countries was conducted. Demographics, tumour characteristics, treatment details, and events dates were collected from medical records. RESULTS: Data from 280 patients were analysed. Before BM, 63% received anti-HER2 treatment. These patients had significantly longer TTBM than those without anti-HER2 treatment (median 33 vs 19 months; P<0.002). After BM, 93% received radiotherapy, 57% received chemotherapy, and 41% received anti-HER2 treatment (trastuzumab and/or lapatinib). Use of both anti-HER2 agents, primarily sequentially, after BM demonstrated the longest survival after BM and was associated with a significant survival benefit over no anti-HER2 treatment (median 26 vs 6 months; hazard ratio 0.37; 95% CI 0.19–0.72). CONCLUSION: Anti-HER2 treatment before BM was associated with longer TTBM. Anti-HER2 treatment after BM was associated with a survival benefit, especially when both trastuzumab and lapatinib were utilised. Nature Publishing Group 2012-09-25 2012-08-23 /pmc/articles/PMC3461152/ /pubmed/22918394 http://dx.doi.org/10.1038/bjc.2012.346 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Yap, Y S
Cornelio, G H
Devi, B C R
Khorprasert, C
Kim, S B
Kim, T Y
Lee, S C
Park, Y H
Sohn, J H
Sutandyo, N
Wong, D W Y
Kobayashi, M
Landis, S H
Yeoh, E M
Moon, H
Ro, J
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
title Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
title_full Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
title_fullStr Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
title_full_unstemmed Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
title_short Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
title_sort brain metastases in asian her2-positive breast cancer patients: anti-her2 treatments and their impact on survival
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461152/
https://www.ncbi.nlm.nih.gov/pubmed/22918394
http://dx.doi.org/10.1038/bjc.2012.346
work_keys_str_mv AT yapys brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT corneliogh brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT devibcr brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT khorprasertc brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT kimsb brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT kimty brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT leesc brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT parkyh brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT sohnjh brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT sutandyon brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT wongdwy brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT kobayashim brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT landissh brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT yeohem brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT moonh brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival
AT roj brainmetastasesinasianher2positivebreastcancerpatientsantiher2treatmentsandtheirimpactonsurvival